An evaluation of outcomes in CELESTIAL based on 13 biomarkers, with baseline levels dichotomized at the median, found that cabozantinib treatment was associated with improved OS and PFS vs placebo in previously treated advanced HCC irrespective of baseline biomarker levels; low baseline levels of MET, hepatocyte growth factor, growth arrest‐specific protein 6, VEGF‐A, angiopoietin‐2 and interleukin‐8 and high levels of insulin‐like growth factor 1 were identified as potential prognostic biomarkers for longer OS with placebo.77 The gene discussed is MET; the disease is hepatocellular carcinoma.